PI3Ks: a new target in GIST and new drugs in trial
Since 2001 GIST treatment has benefited from blocking a single mutant protein, c-KIT. Targeting c-KIT with Gleevec and Sutent has led to years of extended survival for many GIST patients. Unfortunately, cancer is an adaptive [...]